Thai Food and Drug Administration (Thai FDA) Public Assessment Report New Medicinal Products

Total Page:16

File Type:pdf, Size:1020Kb

Thai Food and Drug Administration (Thai FDA) Public Assessment Report New Medicinal Products Thai Food and Drug Administration (Thai FDA) Public assessment report New medicinal products Cresemba® 100 mg hard capsules Isavuconazole E-identifier number: e6200003 Registration number: 1C 15072/63 (NC) Approval date: 9 April 2020 Cresemba® powder for concentrate for solution for infusion 200 mg/vial Isavuconazole E-identifier number: e6200004 Registration number: 1C 15073/63 (NC) Approval date: 9 April 2020 Applicant: Pfizer (Thailand) Limited Product team leader: Worasuda Yoongthong Co-product team leader: Suchat Arammalueangsi Start of the procedure: 25 January 2019 Date of this report: 21 December 2020 TABLE OF CONTENTS 1. Recommendation ................................................................................... 4 2. Executive summary ............................................................................... 4 2.1. Problem statement ............................................................................................. 4 2.2. About the product .............................................................................................. 5 2.3. The development programme/compliance with Thai FDA guidance/scientific advice .... 5 2.4. General comments on compliance with GMP, GLP, GCP ........................................... 5 2.5. Type of application and other comments on the submitted dossier ........................... 5 3. Scientific overview and discussion ........................................................ 5 3.1. Quality aspects .................................................................................................. 5 3.1.1. Introduction .................................................................................................... 5 3.1.2. Active Substance ............................................................................................. 6 3.1.3. Finished Medicinal Product [Hard Capsule] .......................................................... 6 3.1.4. Finished Medicinal Product [Powder for Concentrate for Solution for Infusion] ......... 7 3.2. Non clinical aspects ............................................................................................ 7 3.2.1. Pharmacology ................................................................................................. 7 3.2.2. Pharmacokinetics ............................................................................................ 9 3.2.3. Toxicology .................................................................................................... 12 3.2.4. Discussion on non-clinical aspects .................................................................... 21 3.2.5. Conclusion on non-clinical aspects ................................................................... 21 3.3. Clinical aspects ................................................................................................ 22 3.3.1. Tabular Listing of All Clinical Studies ................................................................ 22 3.3.2. Pharmacokinetics .......................................................................................... 28 3.3.3. Pharmacodynamics ........................................................................................ 36 3.3.4. Discussion on clinical pharmacology ................................................................. 42 3.3.5. Conclusions on clinical pharmacology ............................................................... 43 3.3.6. Clinical efficacy and safety .............................................................................. 44 3.3.7. Discussion on clinical efficacy and safety .......................................................... 49 3.3.8. Conclusions on clinical efficacy and safety ........................................................ 49 3.3.9. Pharmacovigilance system and risk management plan ....................................... 49 4. Benefit risk assessment ....................................................................... 50 5. Conditions for marketing authorisation and product information ........ 50 5.1. Conditions for the marketing authorisation .......................................................... 50 5.2. Summary of product characteristics (SmPC) ........................................................ 50 5.3. Labelling ......................................................................................................... 50 5.4. Patient information leaflet (PIL) ......................................................................... 52 Cresemba® Public assessment report Rev 21 December 2020 Page 2/52 Administrative information Invented name of the medicinal product: CRESEMBA เครสเซมบา INN (or common name) of the active Isavuconazole (as isavucozonium sulfate) substance(s): ไอซาวูโคนาโซล Applicant: Pfizer (Thailand) Limited Applied indication(s): CRESEMBA is indicated in adults for the treatment of • Invasive aspergillosis • Mucomycosis in patients for whom amphotericin B is inappropriate Pharmaco-therapeutic group (ATC Code): (J02) Pharmaceutical form(s) and strength(s): 100 mg capsule, hard; 200 mg/vial powder for concentrate for solution for infusion Declarations This application includes an Active Substance Master File (ASMF): ☐ Yes ☐ No ☒ Not applicable ☐ The assessor confirms that proprietary information on, or reference to, third parties (e.g. ASMF holder) or products are not included in this assessment, including the Product Information, unless there are previous contracts and/or agreements with the third party(ies). ☐ The assessor confirms that reference to ongoing assessments or development plans for other products is not included in this assessment report. Whenever the above box is un-ticked please indicate section and page where confidential information is located (including the Product Information document) here: Cresemba® Public assessment report Rev 21 December 2020 Page 3/52 1. Recommendation Based on the review of the data and the Applicant’s response to the list of questions (LOQs) on quality, safety, efficacy, Thai FDA considers that the application for CRESEMBA indicated in adults for the treatment of • Invasive aspergillosis • Mucomycosis in patients for whom amphotericin B is inappropriate is approvable provided that the applicant commits to perform risk management plan as post authorisation measures to be reported back to Thai FDA within predefined timeframes. A preliminary list of such post- authorisation measures is in section 5.1 of this report. 2. Executive summary 2.1. Problem statement Invasive aspergillosis is a life-threatening infection that is seen predominantly in immunocompromised patients. Patients at greatest risk are those with prolonged neutropenia related to antineoplastic chemotherapy or hematopoietic stem cell transplantation (HSCT), those receiving immunosuppressants following solid organ transplants, advanced HIV infection and those given high doses of corticosteroids. The transmission of fungal spores to the human host is via inhalation and Aspergillus primarily affects the lungs, causing 4 main syndromes: allergic bronchopulmonary aspergillosis (ABPA), chronic necrotizing Aspergillus pneumonia (also termed chronic necrotizing pulmonary aspergillosis [CNPA]), aspergilloma, and invasive aspergillosis. The majority of human illness is caused by Aspergillus fumigatus and Aspergillus niger and, less frequently, by Aspergillus flavus and Aspergillus clavatus. Aspergillus may hematogenously disseminate beyond the lungs and the CNS, cardiovascular system, and other tissues may be infected as a result. Invasive aspergillosis is treated with systemic antifungal agents, such as polyenes (Amphotericin B), mould active triazoles (voriconazole, itraconazole, posaconazole) and echinocandins (caspofungin, micafungin, and anidulafungin). Certain conditions of invasive aspergillosis warrant consideration for surgical resection of the infected focus. Despite the current available antifungal therapies (AFTs) for invasive aspergillosis IFD is still associated with high mortality rates (30-40% in treated and 95% in untreated patients). Mucormycosis is extremely rare and refers to several different diseases caused by infection with fungi in the order of Mucorales. Rhizopus species are the most common causative organisms. Mucoraceae are ubiquitous fungi that are commonly found in soil and in decaying matter. Rhizopus can be found in moldy bread. Most humans are exposed to these organisms on a daily or weekly basis. The major route of infection is via inhalation of conidia; other routes include ingestion and traumatic inoculation. They rarely cause disease because of the low virulence of the organisms; instead, they mainly affect immunocompromised patients. Patients with uncontrolled diabetes mellitus, especially with ketoacidosis, are at high risk. Patients with cancer—especially those who are neutropenic and receiving broad- spectrum antibiotics—as well as individuals receiving immunosuppressive agents—including oral or intravenous steroids and tumor necrosis factor (TNF)–alpha blockers—are at risk. In addition, hematologic cancer patients with opportunistic herpetic infections (e.g., cytomegalovirus) and graft versus host disease are at increased risk. Most mucormycosis infections are life-threatening. Severe infection of the facial sinuses, which may extend into the brain, is the most common presentation. Pulmonary, cutaneous, and gastrointestinal (GI) infections are also recognized. Rhinocerebral disease causes significant morbidity in patients who survive, because treatment usually requires
Recommended publications
  • Comparative Evaluation of Isavuconazonium Sulfate
    Van Matre et al. Ann Clin Microbiol Antimicrob (2019) 18:13 https://doi.org/10.1186/s12941-019-0311-3 Annals of Clinical Microbiology and Antimicrobials RESEARCH Open Access Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center Edward T. Van Matre1 , Shelby L. Evans2, Scott W. Mueller3, Robert MacLaren3, Douglas N. Fish3 and Tyree H. Kiser3,4* Abstract Background: Invasive fungal infections are a major cause of morbidity and mortality. Newer antifungals may provide similar efcacy with improved safety compared to older more established treatments. This study aimed to compare clinically relevant safety and efcacy outcomes in real world patients treated with isavuconazole, voriconazole, or posaconazole. Methods: This single center retrospective matched cohort study evaluated adults between January 2015 and Decem- ber 2017. The primary outcome was a composite safety analysis of antifungal related QTc prolongation, elevated liver function tests (> 5 times ULN), or any documented adverse drug event. Key secondary outcomes included: individual safety events, 30-day readmissions, magnitude of drug interactions with immunosuppressive therapy, and overall cost. Results: A total of 100 patients were included: 34 patients in the voriconazole group and 33 patients within each of the isavuconazole and posaconazole groups. The composite safety outcome occurred in 40% of the total cohort and was diferent between isavuconazole (24.2%), voriconazole (55.9%), and posaconazole (39.4%; p 0.028). Change in QTc (p < 0.01) and magnitude of immunosuppression dose reduction (p 0.029) were diferent between= the three groups. No diferences in mortality, length of stay, readmission, or infection= recurrence were observed between groups (p > 0.05 for all).
    [Show full text]
  • Systemic Antifungal Drug Use in Belgium—
    Received: 7 October 2018 | Revised: 28 March 2019 | Accepted: 14 March 2019 DOI: 10.1111/myc.12912 ORIGINAL ARTICLE Systemic antifungal drug use in Belgium—One of the biggest antifungal consumers in Europe Berdieke Goemaere1 | Katrien Lagrou2,3* | Isabel Spriet4,5 | Marijke Hendrickx1 | Eline Vandael6 | Pierre Becker1 | Boudewijn Catry6,7 1BCCM/IHEM Fungal Collection, Service of Mycology and Aerobiology, Sciensano, Summary Brussels, Belgium Background: Reports on the consumption of systemic antifungal drugs on a national 2 Department of Microbiology and level are scarce although of high interest to compare trends and the associated epi- Immunology, KU Leuven, Leuven, Belgium 3Clinical Department of Laboratory demiology in other countries and to assess the need for antifungal stewardship Medicine, National Reference Centre for programmes. Mycosis, University Hospitals Leuven, Leuven, Belgium Objectives: To estimate patterns of Belgian inpatient and outpatient antifungal use 4Department of Pharmaceutical and and provide reference data for other countries. Pharmacological Sciences, KU Leuven, Methods: Consumption records of antifungals were collected in Belgian hospitals Leuven, Belgium between 2003 and 2016. Primary healthcare data were available for the azoles for 5Pharmacy Department, University Hospitals Leuven, Leuven, Belgium the period 2010-2016. 6 Healthcare‐Associated Infections and Results: The majority of the antifungal consumption resulted from prescriptions of Antimicrobial Resistance, Sciensano, Brussels, Belgium fluconazole and itraconazole in the ambulatory care while hospitals were responsible 7Faculty of Medicine, Université Libre de for only 6.4% of the total national consumption and echinocandin use was limited. Bruxelles (ULB), Brussels, Belgium The annual average antifungal consumption in hospitals decreased significantly by Correspondence nearly 25% between 2003 and 2016, due to a decrease solely in non-university hos- Berdieke Goemaere, Sciensano, Mycology pitals.
    [Show full text]
  • Antifungals, Oral
    Antifungals, Oral Therapeutic Class Review (TCR) July 13, 2018 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. July 2018 Proprietary Information. Restricted Access – Do not disseminate or copy without approval. © 2004-2018 Magellan Rx Management. All Rights Reserved. FDA-APPROVED INDICATIONS Drug Manufacturer FDA-Approved Indication(s) for oral use clotrimazole generic .
    [Show full text]
  • Description Price NDC CABLE PULSE OX (4083) 0 DERMABOND(DNX12) (SEE MIKE) 0 HO-CEMENTED STEM SZ 16 71316216 10671.26 NECK METHA MOD
    Description Price NDC CABLE PULSE OX (4083) 0 DERMABOND(DNX12) (SEE MIKE) 0 HO-CEMENTED STEM SZ 16 71316216 10671.26 NECK METHA MOD. 130DEG./7.5 L NC077K 8451.29 NECK METHA MOD. 130DEG/7.5 L-R NC079K 8400.06 NEEDLE HOLDER WEBSTER P0405 0 POLYP ETRAP 00711099 1202.32 SET CLEANING BRUSHES 0 TIDISHIELD FRAMES/LENS 9210A-100 0 #1613 VENTILATOR CIR 20.01 #1627 VENTILATOR CIR 21.39 #9 WINDOW ENVELOPE(LAB) 0 * 0 ** 3A ANDROSTANEDIOL GLUCURONIDE 345.81 ** ALKALINE PHOSPHATASE (FRAC) 70.66 ** ALKALINE PHOSPHATASE (FRAC) 99.51 ** CSF3R EXON 14/17 MUTATION 787.47 ** FCM EACH ADDITIONAL MARKER 19.76 ** FECAL ALPHA-1 ANTIRYPSIN 183.16 ** FLOW CYTO INTER/REPT 2 TO 8 MARKERS 115.37 ** TRICYCLIC ANTIDEPRESSANTS QNT UR 227.87 ** URINE PHOSPHORUS ASSAY 70.66 **% DELTA 2 HR 0 **% DELTA 4 HR 0 **% DELTA 6 HR 0 **(RI ANTIBODY WESTERN BLOT ATHENA 246.62 *****UR MICROSCOPIC ONLY 61.69 *****URINALYSIS CANCELLATION NOTICE 0 *****URINALYSIS,BIOCHEM REQUEST 0 *****URINALYSIS,BIOCHEM REQUEST 0 ****2HR URINE CREATININE 70.66 ****CHLAMYDIA PNEUMONIAE AB IGG 79.32 ****HLA TYPING FOR CELIAC DISEASE 0 ****PLATELET AB SERUM 250.95 ****PLATELET PHERESIS LEUKO RED IRRAD 2787.85 ****VMA-SERUM 294.23 ***ANAPLASMA AMP DNA PROBE 469.17 ***BLEEDING TIME 62.02 ***HLA-B27 DNA TYPING 0 ***HSV AB IGM 197.59 ***IGG SERUM 172.72 ***IMMUNOGLOBULIN IGA1 SUBCLASS 57.69 ***IMMUNOGLOBULIN IGA2 SUBCLASS 57.69 ***LYME ANTIGEN DETECTION ELISA 167.67 ***LYME IGM ANTIBODY 204.8 ***MOLD ALLERGEN SCREEN 109.61 ***PATHOLOGY GROSS ONLY 0 **1 HR INCUBATION MIX PROGRESSIVE 89.43 **11 DEOXYCORTISOL
    [Show full text]
  • IJP: Drugs and Drug Resistance 8 (2018) 246–264
    IJP: Drugs and Drug Resistance 8 (2018) 246–264 Contents lists available at ScienceDirect IJP: Drugs and Drug Resistance journal homepage: www.elsevier.com/locate/ijpddr Genomic and transcriptomic alterations in Leishmania donovani lines T experimentally resistant to antileishmanial drugs Alberto Rastrojoa,1, Raquel García-Hernándezb,1, Paola Vargasb, Esther Camachoa, Laura Corvoa, Hideo Imamurac, Jean-Claude Dujardinc, Santiago Castanysb, Begoña Aguadoa, ∗∗ ∗ Francisco Gamarrob, , Jose M. Requenaa, a Centro de Biología Molecular “Severo Ochoa” (CSIC-UAM), Universidad Autónoma de Madrid, Madrid, Spain b Instituto de Parasitología y Biomedicina ‘‘López-Neyra’’ (IPBLN-CSIC), Granada, Spain c Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium ARTICLE INFO ABSTRACT Keywords: Leishmaniasis is a serious medical issue in many countries around the World, but it remains largely neglected in Leishmania donovani terms of research investment for developing new control and treatment measures. No vaccines exist for human Genome use, and the chemotherapeutic agents currently used are scanty. Furthermore, for some drugs, resistance and Transcriptome treatment failure are increasing to alarming levels. The aim of this work was to identify genomic and tran- Trivalent antimony criptomic alterations associated with experimental resistance against the common drugs used against VL: tri- Amphotericin B valent antimony (SbIII, S line), amphotericin B (AmB, A line), miltefosine (MIL, M line) and paromomycin (PMM, Miltefosine ff fi Paromomycin P line). A total of 1006 di erentially expressed transcripts were identi ed in the S line, 379 in the A line, 146 in 24-Sterol methyltransferase the M line, and 129 in the P line. Also, changes in ploidy of chromosomes and amplification/deletion of par- D-lactate dehydrogenase ticular regions were observed in the resistant lines regarding the parental one.
    [Show full text]
  • ASTELLAS Factsheet 1.Pdf
    Astellas is actively committed to the infectious disease field. Our infectious disease portfolio includes three classes of drugs: AmBisome® (amphotericin B) liposome for injection, CRESEMBA® (isavuconazonium sulfate), and MYCAMINE® (micafungin sodium) for injection. We continue to expand the knowledge base of this therapeutic area and empower physicians to make evidence-based clinical decisions. Our proud history of collaborating with clinical investigators has provided opportunities around the world to study compounds that have the potential to be significant breakthroughs and allows us to generate and publish key information about these advances. In fact, Astellas pioneered the empiric antifungal clinical trial and has performed some of the world’s largest clinical trials in fungal infections. AmBisome® is indicated for the following: • The incidence of some common adverse events was • Empirical therapy for presumed fungal infection in greater in patients taking AmBisome compared to febrile neutropenic patients patients taking Abelcet in the clinical study noted above • Treatment of Cryptococcal Meningitis in HIV-infected including: chest pain, hypocalcemia, hypomagnesemia, patients confusion, headache, and rash • Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to Important Safety Information amphotericin B deoxycholate, or in patients where renal Despite significantly less nephrotoxicity observed at a dose impairment or unacceptable toxicity precludes the use range of 1.5–6.0 mg/kg/day compared to amphotericin B of amphotericin B deoxycholate deoxycholate at a dose range of 0.3–1.2 mg/kg/day in a • Treatment of visceral leishmaniasis; in randomized clinical trial, dose-limiting renal toxicity may still immunocompromised patients with visceral be observed with AmBisome.
    [Show full text]
  • Nystatin and Triamcinolone Acetonide Cream, USP Nystatin And
    FRONT BACK Nystatin and Triamcinolone Acetonide Cream, USP PK-1111-3 corticosteroids. 45 Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to Nystatin and Triamcinolone Acetonide Ointment, USP systemic toxicity (see PRECAUTIONS, Pediatric Use). Rx only If irritation or hypersensitivity develops with the combination nystatin and triamcinolone acetonide, treatment should be discontinued and appropriate therapy instituted. FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE Information for the Patient: Patients using this medication should receive the following information and DESCRIPTION: Nystatin and Triamcinolone Acetonide Cream and Ointment for dermatologic use contain the instructions: antifungal agent nystatin and the synthetic corticosteroid triamcinolone acetonide. 1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes. Nystatin is a polyene antimycotic obtained from Streptomyces noursei. It is a yellow to light tan powder with a 2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed. cereallike odor, very slightly soluble in water, and slightly to sparingly soluble in alcohol. Structural formula: 3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occluded (see CH3 DOSAGE AND ADMINISTRATION). O H CH3 4. Patients should report any signs of local adverse reactions. O H HO OH H2N 5. When using this medication in the inguinal area, patients should be advised to apply the cream or ointment OH OH sparingly and to wear loose fitting clothing. CH3 H H H3C 6. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being OH O COOH treated in the diaper area, as these garments may constitute occlusive dressings.
    [Show full text]
  • WO 2017/009265 Al 19 January 2017 (19.01.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/009265 Al 19 January 2017 (19.01.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A01N 31/06 (2006.01) A01N 37/04 (2006.01) kind of national protection available): AE, AG, AL, AM, A0 37/00 (2006.01) A01P 1/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A0 37/02 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/EP2016/066368 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 8 July 2016 (08.07.2016) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 15 12 135.3 10 July 2015 (10.07.2015) GB GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: IPABC LTD [GB/GB]; The Die-Pat Centre, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Broad March, Broad March, Daventry, Northamptonshire DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, NN1 1 4HE (GB).
    [Show full text]
  • Isavuconazonium
    Drug and Biologic Coverage Criteria Effective Date ............................................ 8/1/2020 Next Review Date… ..................................... 8/1/2021 Coverage Policy Number ................................ P0011 Isavuconazonium Table of Contents Related Coverage Resources Medical Necessity Criteria ................................... 1 FDA Approved Indications ................................... 2 Recommended Dosing ........................................ 2 Background .......................................................... 2 References .......................................................... 3 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the
    [Show full text]
  • 207500S005,207501S004lbl.Pdf
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Infusion-related reactions were reported during intravenous These highlights do not include all the information needed to use administration of CRESEMBA. Discontinue the infusion if these CRESEMBA® safely and effectively. See full prescribing information for reactions occur. (5.2) CRESEMBA®. • Hypersensitivity Reactions: Serious hypersensitivity and severe skin CRESEMBA® (isavuconazonium sulfate) capsules, for oral use reactions, such as anaphylaxis or Stevens Johnson syndrome, have been CRESEMBA® (isavuconazonium sulfate) for injection, for intravenous reported during treatment with other azole antifungal agents. use Discontinue CRESEMBA for exfoliative cutaneous reactions. (5.3) Initial U.S. Approval: 2015 • Embryo-Fetal Toxicity: CRESEMBA may cause fetal harm when ------------------------RECENT MAJOR CHANGES----------------------------­ administered to a pregnant woman. Advise pregnant women of the Warnings and Precautions, Embryo-Fetal Toxicity (5.4) 11/2019 potential risk to the fetus. Advise females of reproductive potential to ---------------------------INDICATIONS AND USAGE---------------------------­ use an effective method of contraception. (5.4, 8.1, 8.3) CRESEMBA® is an azole antifungal indicated for use in the treatment of: • Drug Interactions: Review patient’s concomitant medications. Several • Invasive aspergillosis. (1.1) drugs may significantly alter isavuconazole concentrations. Isavuconazole may alter concentrations of several drugs. (5.5, 7, 12.3) • Invasive mucormycosis. (1.2)
    [Show full text]
  • Amphotericin B Amphocil
    Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended Amphotericin B Amphocil Abelcet DE/W/009/pdWS/001 Rapporteur: Germany Finalisation procedure (day 120): 24.11.2017 Amphotericin B DE/W/009/pdWS/001 Seite 1 TABLE OF CONTENTS I. Executive Summary ....................................................................................................... 4 II. RecommendatioN .......................................................................................................... 4 III. INTRODUCTION ............................................................................................................. 6 IV. SCIENTIFIC DISCUSSION .............................................................................................. 7 IV.1 Information on the pharmaceutical formulation used in the clinical studies .............. 7 IV.2 Non-clinical aspects ................................................................................................................... 9 IV.3 Clinical aspects .......................................................................................................................... 10 V. MEMBER STATES Overall Conclusion AND RECOMMENDATION ........................... 31 VI. List of Medicinal products and marketing authorisation holders involved ............. 33 Amphotericin B DE/W/009/pdWS/001 Page 2/33 ADMINISTRATIVE INFORMATION Invented name of the medicinal See section VI product(s): INN (or common name) of the active Amphotericin B substance(s):
    [Show full text]
  • Adaptation of Aspergillus Niger to Multiple Agents Whose Action Mechanisms Are Different
    Jpn. J. Med. Mycol. Vol. 36, 19-24, 1995 ISSN 0916-4804 Original Article Adaptation of Aspergillus niger to Multiple Agents Whose Action Mechanisms are Different Hideaki Matsuoka1, Jong-Chul Park1, Yasuyuki Nemoto1, Satoru Yamada2, Weimin Jing3, Yuansong Chen3, Kosuke Takatori4, Hiroshi Kurata5 1Department of Biotechnology, Faculty of Technology, Tokyo University of Agriculture and Technology, 2-24-16, Nakamachi, Koganei, Tokyo 184, Japan 2Research and Development Division, Bio-Liken Inc., 1-5-8, Iwamotocho, Chiyoda-ku, Tokyo 101, Japan 3Research and Development Division, Hidan Co. Ltd., 627, Hananoi, Kashiwa, Chiba 277, Japan 4Hatano Research Institute, Food & Drug Safety Center, 729-5, Ochiai, Hadano, Kanagawa 257, Japan 5The Tokyo Kembikyoin Foundation, 4-8-32, Kudanminami, Chiyoda-ku, Tokyo 102, Japan (Received: 9, August 1994. Accepted: 9, September 1994] Abstract Adaptation of Aspergillus niger to amphotericin B (AMPH) and two imidazoles (miconazole (MCZ) and ketoconazole (KCZ)) was observed at a single hypha level with a continuous measurement system. It was found that a test hypha adapted to MCZ or KCZ was also adapted to AMPH but that a hypha adapted to AMPH was not adapted either to MCZ or KCZ. These adaptation phenomena to respective agents did not occur after incubation in the medium supplemented with ergosterol. The cross adaptation phenomena were suspected to be due to modification of the synthesis pathway of ergosterol and related derivatives. Key words: adaptation, hyphal growth rate, Aspergillus niger, amphotericin B, miconazole, ketoconazole. rienced by many mycologists and microbiologists Introduction 5-9). The newly developed BCT system has dem- A single hypha-based microbioassay has recently onstrated those adaptation phenomena much more been proposed and applied to the evaluation of clearly by tracing the same hypha throughout.
    [Show full text]